Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/
Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have been rarely studied. This is a multicenter, retrospective, observational study in patients with T2D and CKD with glycosylated hemoglobin A1c (HbA1c) of 7.5-9.5% treated with subcutaneous semaglutide for 12 months in real-world clinical practice.
Conclusion/Relevance: In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.
-
Dr HamidAugust 23, 2022Patients with T2D and CKD who develop macroalbuminuria have a greater risk of cardiovascular disease mortality than progression to ESKD